Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elecoglipron master protocol in obesity or overweight with or without type 2 diabetes
PACTR202607874630774Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elecoglipron in obesity, Overweight and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Percent body weight loss. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
elecoglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202607874630774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607874630774.